Penserra Capital Management LLC Has $60,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Penserra Capital Management LLC cut its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 81.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 126 shares of the pharmaceutical company’s stock after selling 548 shares during the quarter. Penserra Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $60,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of VRTX. Capital World Investors grew its holdings in Vertex Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock worth $11,406,667,000 after purchasing an additional 1,514,993 shares during the period. Vanguard Group Inc. grew its holdings in Vertex Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company’s stock worth $9,366,113,000 after purchasing an additional 98,654 shares during the period. Capital Research Global Investors grew its holdings in Vertex Pharmaceuticals by 15.8% in the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock worth $4,199,713,000 after purchasing an additional 1,426,746 shares during the period. Wellington Management Group LLP grew its holdings in Vertex Pharmaceuticals by 23.3% in the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company’s stock worth $2,382,407,000 after purchasing an additional 1,117,214 shares during the period. Finally, Loomis Sayles & Co. L P grew its holdings in Vertex Pharmaceuticals by 23.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 3,772,789 shares of the pharmaceutical company’s stock worth $1,519,302,000 after purchasing an additional 704,575 shares during the period. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on VRTX. Wolfe Research cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a report on Wednesday, May 7th. Erste Group Bank lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 23rd. Leerink Partnrs lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 6th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $535.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $511.62.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $468.85 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The stock has a market capitalization of $120.40 billion, a price-to-earnings ratio of -119.60 and a beta of 0.41. The company has a fifty day moving average of $447.71 and a 200-day moving average of $460.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same period last year, the company posted $4.76 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 2.6% on a year-over-year basis. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.